| Nov 11 |
IMNN: Meeting with FDA in Preparation for Phase 3 Ovarian Cancer Trial
|
| Nov 7 |
Imunon, Inc. (IMNN) Q3 2024 Earnings Call Transcript
|
| Nov 7 |
IMUNON Presents Positive Data from Phase 2 OVATION 2 Clinical Trial of IMNN-001 in Advanced Ovarian Cancer at SITC 39th Annual Meeting
|
| Nov 7 |
Imunon GAAP EPS of -$0.34 beats by $0.06
|
| Nov 7 |
IMUNON Reports Third Quarter 2024 Financial Results and Provides Business Updates
|
| Nov 6 |
Imunon Q3 2024 Earnings Preview
|
| Oct 31 |
IMUNON to Hold Third Quarter 2024 Financial Results and Business Update Conference Call on Thursday, November 7, 2024
|
| Oct 30 |
IMUNON to Present Phase 2 Data of IMNN-001 in Treatment of Newly Diagnosed Ovarian Cancer at SITC 39th Annual Meeting
|
| Sep 9 |
UPDATE - IMUNON’s Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive Management
|
| Sep 9 |
IMUNON’s Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive Management
|
